D

    Dermata Therapeutics Inc (DRMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.29
    -0.05 (-3.73%)

    Market Cap: $6.64M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(16/21)
    Avg Surprise
    +0.45%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.63
    Range$-0.63 - $-0.63
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.84-33.3%
    60d ago$-0.84-33.3%
    30d ago$-0.61+3.2%
    7d ago$-0.61+3.2%
    Current$-0.63
    Revenue Consensus
    $25000
    Range$25000 - $25000
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.46
    Range$-0.46 - $-0.46
    1 analysts
    Revenue Consensus
    $75000
    Range$75000 - $75000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.46---
    Sep 26EST
    		-$-0.63---
    Jun 26
    		$-0.74$-0.55-34.55%Miss+55.4%
    Mar 26
    		$-0.48$-0.53+9.43%Beat+61.6%
    Dec 25
    		$-1.52$-1.54+1.30%Beat+88.7%
    Sep 25
    		$-1.65$-1.59-3.77%Miss+91.9%
    Jun 25
    		$-1.66$-2.90+42.76%Beat+96.0%
    Mar 25
    		$-1.25$-0.45-178.11%Miss+73.4%
    Dec 24
    		$-13.40$-15.00+10.67%Beat-6281.0%
    Sep 24
    		$-20.40$-26.40+22.73%Beat+74.8%
    Jun 24
    		$-41.80$-37.90-10.29%Miss+55.8%
    Mar 24
    		$-4.70N/A+91.30%Beat+98.6%
    Dec 23
    		$-0.21N/A+73.08%Beat+99.9%
    Sep 23
    		$-81.00$-94.50+14.29%Beat+83.1%
    Jun 23
    		$-94.50$-138.00+31.52%Beat+83.6%
    Mar 23
    		$-340.50$-397.50+14.34%Beat+57.0%
    Dec 22
    		$-288.00$-480.00+40.00%Beat-6823.1%
    Sep 22
    		$-480.00$-528.00+9.09%Beat+76.7%
    Jun 22
    		$-576.00$-768.00+25.00%Beat-5042.9%
    Mar 22
    		$-792.00$-960.00+17.50%Beat-65566.2%
    Dec 21
    		$-4.16$-5.68+26.76%Beat-459.4%
    Sep 21
    		$-2064.00$-600.00-244.00%Miss-
    Jun 21
    		$-11.20N/A+50.35%Beat-
    Dec 20
    		$-1.21$0.00N/AMiss-
    Dec 19
    		$-0.74$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.29EV/EBITDA0.58x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-183.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.81xQuick Ratio2.73x
    Trading Statistics
    Beta0.66Avg Volume2.08M
    52-Week High$6.2252-Week Low$0.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.48
    SMA 20$1.36
    SMA 50$1.31
    SMA 200$1.63
    EMA 10$1.43
    EMA 20$1.40
    EMA 50$1.34
    EMA 200$2.18

    MACD

    Line: 0.05Signal: 0.06Hist: -0.01

    ADX

    ADX: 25.6+DI: 23.5-DI: 23.2

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down20.0
    PSAR$1.72

    Bollinger Bands

    Upper Band$1.76
    Lower Band$0.97
    %B Position5764%(Upper)
    Band Width0.40

    RSI (14-Day)

    Neutral
    46.0

    Momentum Oscillators

    Stoch %K40.5
    Stoch %D61.1
    Williams %R-79.6
    ROC (10d)-11.6%
    Momentum-0.17
    CCI (20d)-28.1
    MFI (14d)95.8

    Volatility Measures

    ATR (14d)$0.15(11.6%)
    StdDev (20d)0.20
    Hist Vol144.9%(High)

    Volume Flow

    VWAP$1.30
    OBV214.3M
    AD Line5.7B
    CMF (20d)-0.352

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.0x(Low)
    VWMA (20d)$1.23

    Pivot Points

    R3$1.74
    R2$1.66
    R1$1.50
    Pivot Point$1.42
    S1$1.26
    S2$1.18
    S3$1.02

    Advanced Oscillators

    TSI10.53
    Ultimate Osc50.6
    KST174.91

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$3.01M$1.93M$1.90M$1.76M$1.77M$2.34M$3.20M$3.23M$2.88M$3.20M$2.22M$1.81M
    R&D$212,563$383,724$526,620$504,387$617,835$1.28M$2.19M$2.40M$2.01M$1.60M$1.14M$902,977
    SG&A$2.80M$1.54M$1.37M$1.26M$1.15M$1.06M$1.01M$824,294$874,640$1.60M$1.08M$909,001
    Operating Income$-3,013,567$-1,926,382$-1,900,393$-1,760,671$-1,772,731$-2,339,803$-3,200,287$-3,225,653$-2,883,742$-3,203,560$-2,219,832$-1,811,978
    Interest Income$46,504$78,676$38,505$68,682$71,638$36,216$49,350$52,497$54,636$69,298$85,859$92,767
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-2,967,063$-1,847,706$-1,861,888$-1,691,989$-1,701,093$-2,303,587$-3,150,937$-3,173,156$-2,829,106$-3,134,262$-2,133,973$-1,719,211
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,967,063$-1,847,706$-1,861,888$-1,691,989$-1,701,093$-2,303,587$-3,150,937$-3,173,156$-2,829,106$-3,134,262$-2,133,973$-1,719,211
    EBITDA$-3,013,567$-1,926,382$-1,900,393$-1,760,671$-1,772,731$-2,339,803$-3,200,287$-3,225,653$-2,883,742$-3,203,560$-2,219,832$-1,811,978
    EBIT$-3,013,567$-1,926,382$-1,900,393$-1,760,671$-1,772,731$-2,339,803$-3,200,287$-3,225,653$-2,883,742$-3,203,560$-2,219,832$-1,811,978
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DRMA

    News

    Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

    Dermata Therapeutics (Nasdaq:DRMA) has officially launched its Tome Foundational Treatment, the first product under its new Tome skincare brand. This once-weekly skin renewal treatment, powered by the Bioneedle™ ingredient, is now available for direct purchase or subscription at tomeskincare.com. The launch signifies Dermata's strategic shift into the direct-to-consumer skincare market, leveraging its dermatology expertise to offer science-driven products designed to simplify skincare routines.

    ACCESS Newswire•8/25/26•
    Bullish

    Dermata Therapeutics Stock Price Forecast. Should You Buy DRMA?

    StockInvest.us has upgraded Dermata Therapeutics, Inc. (DRMA) to a "Buy Candidate" with a technical score of 1.48, following a 2.90% stock price increase on the last trading day. The company's stock shows lower volatility than the market and efficient cash conversion. Despite some negative signals, the overall short-term trend is positive, with a forecasted rise of 3.63% over the next three months.

    StockInvest.us•8/22/26•
    Bullish

    Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

    Dermata Therapeutics, Inc. has announced that preorders are now open for its first direct-to-consumer skincare product, Tome Foundational Treatment. The once-weekly topical mask for skin renewal is set to begin shipping on August 25, 2026. This launch marks Dermata's entry into the consumer skincare market with a product designed to offer professional-grade results from home using natural ingredients.

    Newswire•8/21/26•
    Somewhat-Bullish

    Dermata opens preorders for Tome skincare product By Investing.com

    Dermata Therapeutics Inc. has opened preorders for its first direct-to-consumer skincare product, Tome Foundational Treatment, which is set to ship on August 25, 2026. The product, retailing for $178 with a subscriber discount, is a once-weekly topical mask featuring Bioneedle, an ingredient derived from freshwater sponges. This launch marks a significant milestone for Dermata as it commercializes its initial offering in a planned portfolio of Tome skincare products.

    Investing.com Nigeria•8/21/26•
    Bullish

    Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    Dermata Therapeutics has announced a $3.4 million private placement priced at-the-market under Nasdaq rules, involving the issuance of common stock and warrants. The offering is expected to generate an additional potential gross proceeds of approximately $6.7 million if all warrants are fully exercised. Proceeds are intended for general corporate purposes, including consumer research, product launches, and potential acquisitions.

    Yahoo Finance•8/18/26•
    Somewhat-Bullish

    Frequently Asked Questions About DRMA

    Does DRMA pay dividends?
    Dermata Therapeutics Inc (DRMA) does not currently pay a regular dividend.
    What is DRMA's market cap?
    Dermata Therapeutics Inc (DRMA) has a market capitalization of $6.64M with a current stock price of $1.29.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In